Starsource Multitrade Ltd
The Chemo Pharma Laboratories Limited was established in 1942 and was making Pharmaceuticals and bulk drugs. However due to increased competition, Company disposed the business. Company is in advanced stage of negotiation to diversify and take over a sick company[1]
- Market Cap ₹ 13.9 Cr.
- Current Price ₹ 92.8
- High / Low ₹ 153 / 72.0
- Stock P/E
- Book Value ₹ 8.60
- Dividend Yield 0.00 %
- ROCE -164 %
- ROE -164 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 10.8 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 27.9%
- Company has a low return on equity of -31.6% over last 3 years.
- Company has high debtors of 337 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.53 | 0.60 | |
| 0.12 | 0.17 | 0.27 | 0.34 | 0.56 | 0.48 | 0.34 | 0.41 | 0.20 | 0.19 | 0.12 | 12.40 | 0.64 | |
| Operating Profit | -0.12 | -0.17 | -0.27 | -0.34 | -0.56 | -0.48 | -0.34 | -0.41 | -0.20 | -0.19 | -0.12 | -11.87 | -0.04 |
| OPM % | -2,239.62% | -6.67% | |||||||||||
| 0.50 | 0.49 | 5.61 | 1.11 | 0.82 | 1.00 | 0.67 | 0.79 | 0.30 | 1.84 | 0.62 | 0.02 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | 0.38 | 0.32 | 5.34 | 0.77 | 0.26 | 0.50 | 0.31 | 0.36 | 0.08 | 1.64 | 0.49 | -11.85 | -0.04 |
| Tax % | 26.32% | 31.25% | 12.17% | 85.71% | 19.23% | 16.00% | 19.35% | -55.56% | 37.50% | 26.83% | 32.65% | 0.00% | |
| 0.28 | 0.22 | 4.68 | 0.10 | 0.21 | 0.42 | 0.25 | 0.56 | 0.05 | 1.20 | 0.34 | -11.85 | -0.04 | |
| EPS in Rs | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -79.00 | -0.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 100% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 32% |
| 3 Years: | 38% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -18% |
| 3 Years: | -32% |
| Last Year: | -164% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
| Reserves | 3.62 | 3.84 | 8.52 | 8.62 | 8.83 | 9.24 | 9.49 | 10.05 | 10.10 | 11.30 | 11.64 | -0.21 |
| 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.46 | 0.20 | 0.58 | 0.13 | 0.09 | 0.22 | 0.06 | 0.11 | 0.02 | 0.21 | 0.21 | 0.52 | |
| Total Liabilities | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 13.01 | 13.35 | 1.81 |
| 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 | 0.01 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.68 | 1.68 | 0.02 | 0.02 | 0.04 | 0.02 | 0.04 | 2.94 | 3.03 | 4.40 | 0.01 | 0.01 |
| 3.90 | 3.86 | 10.69 | 10.23 | 10.38 | 10.87 | 10.96 | 8.68 | 8.56 | 8.59 | 13.33 | 1.80 | |
| Total Assets | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 13.01 | 13.35 | 1.81 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -0.43 | 6.41 | -1.66 | -5.48 | 4.83 | -0.41 | -0.33 | -0.68 | 0.72 | -0.28 | -10.62 | |
| 0.25 | 0.49 | 0.52 | 1.08 | 0.79 | 1.01 | -0.19 | 0.97 | 0.63 | -0.52 | 10.46 | 0.01 | |
| 0.00 | 0.00 | -0.50 | 1.37 | 0.00 | 0.00 | 1.96 | -2.12 | -0.08 | -0.15 | -0.16 | 0.00 | |
| Net Cash Flow | 0.20 | 0.06 | 6.43 | 0.79 | -4.70 | 5.84 | 1.36 | -1.49 | -0.13 | 0.05 | 10.02 | -10.61 |
| Free Cash Flow | -0.05 | -0.43 | 6.41 | -1.66 | -5.48 | 4.83 | -0.41 | -0.33 | -0.68 | 0.72 | -0.28 | -10.62 |
| CFO/OP | -25% | 206% | -2,615% | 294% | 970% | -1,023% | 94% | 66% | 335% | -468% | 67% | 89% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 337.45 | |||||||||||
| Inventory Days | 0.00 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 337.45 | |||||||||||
| Working Capital Days | 874.62 | |||||||||||
| ROCE % | 7.62% | 6.12% | 3.62% | 7.60% | 2.54% | 4.75% | 2.85% | 1.33% | 0.78% | 13.28% | 5.17% | -164.24% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Inter-Corporate Deposit (ICD) Outstanding INR Thousands |
|
|||||||||
| Investment in Mutual Funds INR Thousands |
||||||||||
| Number of Equity Investee Companies count |
||||||||||
| Number of Mutual Fund Schemes Held count |
||||||||||
| Bank Term Deposits (HDFC FD and Other Bank Balances) INR Thousands |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement for Unaudited Financial Result for the Quarter ended on June 30, 2026.
- Unaudited Financial Result For The Quarter Ended On June 30, 2026
-
Board Meeting Outcome for Board Meeting Held On August 14, 2026.
- Board approved Q1 FY27 standalone results for quarter ended June 30, 2026; profit of Rs 209.84 thousand.
-
Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter Ended On June 30, 2026.
- Board meeting on Aug 14, 2026 to consider Q1 FY27 unaudited results; trading window closed from July 1.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) RTA certificate for quarter ended June 30, 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Background[1]
The Chemo Pharma Laboratories Limited was established in 1942 and has been making pharmaceuticals and diversified into bulk drugs. However due to increase in competition and flow of new drugs, Company disposes their business and pay all its liabilities and dues. Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential. The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals.